- Hong Kong
- /
- Healthcare Services
- /
- SEHK:928
King International Investment Full Year 2024 Earnings: EPS: HK$0.01 (vs HK$0.017 loss in FY 2023)
King International Investment (HKG:928) Full Year 2024 Results
Key Financial Results
- Revenue: HK$233.7m (up 4.4% from FY 2023).
- Net income: HK$15.8m (up from HK$25.2m loss in FY 2023).
- Profit margin: 6.8% (up from net loss in FY 2023).
- EPS: HK$0.01 (up from HK$0.017 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
King International Investment shares are up 5.7% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for King International Investment that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if King International Investment might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:928
King International Investment
An investment holding company, provides genetic testing and health data analysis services in the People’s Republic of China and Hong Kong.
Adequate balance sheet slight.